NPPA and pulmonary arterial hypertension: In these analyses, the PAH SOC Riociguat did not lead to significant improvements in Fulton’s Index, cardiomyocyte size, RV vascularization, ANP mRNA expression levels, or RV fibrosis, and an improved pattern of adaptive hypertrophy was not observed upon Riociguat treatment (Supplementary Table 5).